Safety Reading Notes

Read safety context beside the research guide.

The ABHD12 source set includes safety-context rows around 2-AG biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms. Public reading should keep these rows beside the benefit-oriented buckets, because product identity, dose, route, population, impairment, interactions, and adverse-event context can change what a study means. PMID 32203086

Mapped evidence with interpretation limits: insufficient (1)

PubMed For Dummies Article

ABHD12 Evidence Review: the long-form source walk-through

Quick read
  • ABHD12 currently has 17 source-backed evidence row(s), so this page should be read as a research guide rather than a single conclusion. PMID 32203086
  • The evidence classes most visible in the row language are insufficient (9), preclinical (3), mechanistic or pharmacological (3), and preliminary human (2). PMID 34179865
  • The study-design language most visible in the row language is Narrative or expert review (9), Animal study (5), and Human clinical study (1). PMID 40269679
  • The repeated topics are endocannabinoid enzyme activity or metabolic mechanisms (16), and 2-AG biology, receptor pharmacology, metabolism, physiology, or safety-releva... (1), which tells the reader where to start opening PubMed and DOI links. PMID 34217798

Start with the research question

ABHD12 is built from 17 source-backed evidence row(s) and 16 research source(s). The current evidence classes read as insufficient (9), preclinical (3), mechanistic or pharmacological (3), and preliminary human (2), and the study-design language most often reads as Narrative or expert review (9), Animal study (5), and Human clinical study (1). PMID 32203086

The row-level question is not simply whether ABHD12 is "good" or "bad." The useful question is what each row studied, what evidence class it received, and whether the source is close to the reader's actual question. The most repeated row topics are endocannabinoid enzyme activity or metabolic mechanisms (16), and 2-AG biology, receptor pharmacology, metabolism, physiology, or safety-releva... (1). PMID 20047159

Human evidence 2 rows

Rows involving human participants, patients, or clinical source language. These rows are closer to everyday reader questions, but still depend on population, dose, route, comparator, and endpoint. PMID 20047159

Preclinical evidence 3 rows

Animal, cellular, or model-based rows. These can explain why a topic is being studied, but they should not be read as human-health instructions. PMID 34959715

Mechanistic evidence 3 rows

Rows about receptors, enzymes, channels, metabolism, binding, signaling, or pharmacology. These explain plausibility without proving a consumer outcome. PMID 41092478

Limits and uncertainty 9 rows

Rows where safety, tolerability, risk, product limits, or insufficient evidence need to stay visible next to the rest of the article. PMID 24346263

The lane labels are not a quality score. They are a reading method: keep human evidence, preclinical evidence, mechanisms, and uncertainty in separate mental boxes before deciding what a source can actually support. PMID 39245706

Where this page has the most source density

The largest bucket surfaced for this page is endocannabinoid enzyme activity or metabolic mechanisms. That does not automatically mean the topic is settled; it means this is where the current source trail is densest. The next visible bucket is endocannabinoid enzyme activity or metabolic mechanisms, which gives readers another way to see what the literature repeatedly circles. PMID 32203086

Source density should be read with evidence posture. A bucket can contain many rows and still be limited if the studies are indirect, mixed, preclinical, product-specific, or mostly review-level. The paragraphs below name the buckets directly and keep each explanation connected to a source record. PMID 20047159

Bucket chapters: what the literature is circling

endocannabinoid enzyme activity or metabolic mechanisms

12 research sources 12 rows (300-314) Developed but mixed human research summary: insufficient (6), mechanistic or pharmacological (3), preclinical (2), preliminary human (1)

ABHD12 appears in rows about endocannabinoid enzyme activity or metabolic mechanisms mechanisms. It currently draws from 12 research source(s), and mechanistic evidence should stay separate from human-outcome evidence. PMID 32203086

Read this bucket as closer to a real-world question, then check the study population, dose, product, comparator, and endpoint before generalizing beyond the source. PMID 32203086

  • Evidence row 300

    Endocannabinoids modulates endocannabinoid enzyme activity or metabolic mechanisms; evidence class: insufficient (study design: Narrative or expert review; outcome measure: endocannabinoid enzyme activity or metabolic mechanisms). PMID 32203086

  • Evidence row 314

    Endocannabinoids modulates endocannabinoid enzyme activity or metabolic mechanisms; evidence class: preliminary human (population or model: Human participants or patients mentioned; outcome measure: endocannabinoid enzyme activ... PMID 22969151

endocannabinoid enzyme activity or metabolic mechanisms

3 research sources 3 rows (303-311) Developed but mixed human research summary: insufficient (2), preliminary human (1)

ABHD12 appears in rows about endocannabinoid enzyme activity or metabolic mechanisms mechanisms. It currently draws from 3 research source(s), and mechanistic evidence should stay separate from human-outcome evidence. PMID 20047159

Read this bucket as closer to a real-world question, then check the study population, dose, product, comparator, and endpoint before generalizing beyond the source. PMID 20047159

  • Evidence row 303

    THC modulates endocannabinoid enzyme activity or metabolic mechanisms; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: endocann... PMID 20047159

  • Evidence row 311

    THC modulates endocannabinoid enzyme activity or metabolic mechanisms; evidence class: preliminary human (population or model: Pregnancy, lactation, or reproductive context mentioned; outcome measure: endocannabinoid enzyme act... PMID 32829065

2-AG biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms

1 research source 1079 Mapped evidence with interpretation limits: insufficient (1)

ABHD12 appears in rows studying 2-AG biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms. It currently draws from 1 research source(s), so the population, dose, route, and endpoint should be checked before reading across contexts. PMID 21418147

Read this bucket as safety context first. It belongs beside any benefit-oriented rows because risk, route, dose, product quality, co-exposures, and population can change what a source means. PMID 21418147

  • Evidence row 1079

    2-AG studied for 2-AG biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: insufficient (study design: Narrative or expert review; outcome measure: 2-AG biology, receptor pharma... PMID 21418147

endocannabinoid enzyme activity or metabolic mechanisms

1 research source 203 Preclinical research summary: preclinical (1)

ABHD12 appears in rows about endocannabinoid enzyme activity or metabolic mechanisms mechanisms. It currently draws from 1 research source(s), and mechanistic evidence should stay separate from human-outcome evidence. PMID 34179865

Read this bucket as closer to a real-world question, then check the study population, dose, product, comparator, and endpoint before generalizing beyond the source. PMID 34179865

  • Evidence row 203

    CBDV modulates endocannabinoid enzyme activity or metabolic mechanisms; evidence class: preclinical (population or model: Human participants or patients mentioned; study design: Human clinical study; outcome measure: endocannab... PMID 34179865

Human evidence, mechanisms, and safety are different lanes

This page currently separates human evidence (2 row(s)), mechanistic evidence (3 row(s)), and safety/tolerability context (0 row(s)). That separation is the heart of the site. Mechanistic evidence can make a topic biologically interesting, but it should not silently become a human outcome. PMID 32203086

Human evidence still depends on population, dose, route, duration, product identity, and endpoint. Safety rows belong in the same reading path as benefit-oriented rows because formulation, co-exposures, prescription medications, impairment context, and higher-risk populations can change how close a source is to a reader's question. PMID 20047159

What this does and does not mean

  • It means the page has a traceable source trail. It does not mean every bucket has the same clinical strength. PMID 17346227
  • It means mechanisms, animal models, human studies, safety rows, and insufficient-evidence rows are being kept visible as separate evidence types. PMID 39747798
  • It does not turn a preclinical mechanism into a consumer recommendation, and it does not treat one product, dose, route, or population as interchangeable with another. PMID 30564946

How to use the source table

The source-backed evidence table below is the audit trail. Each row keeps a public sentence connected to a source record when a PubMed ID or DOI is available. If a sentence feels important, the reader should be able to click through, inspect the study type, and decide whether the source is close to the question they care about. PMID 32203086

This is why the public page is intentionally layered. The top gives the reader a fast orientation. The bucket table groups repeated rows into readable topics. The article body explains the buckets using the actual evidence-row language. The source notes below walk through every evidence row before the source table repeats the technical trace. PMID 20047159

Source-reading checklist for ABHD12

  1. Open the linked PubMed or DOI record. PMID 32829065
  2. Check whether the source studied humans, animals, cells, chemistry, pharmacology, product testing, or a review of prior literature. PMID 21418147
  3. Compare the source product, dose, route, population, and endpoint to the question being asked. PMID 30075103
  4. Look for safety, tolerability, drug-interaction, impairment, pregnancy, pediatric, psychiatric, cardiovascular, and product-quality context before treating the bucket as settled. PMID 22969151
  5. Return to the evidence table when the article summary sounds too broad; the row is the audit unit. PMID 32203086

Source Notes

ABHD12 source-by-source reading notes

These notes pull every evidence row on this page into the readable article body before the source table repeats the audit trail. Each note keeps the row language beside the PubMed or DOI link when available.

  1. Evidence row 203

    CBDV modulates endocannabinoid enzyme activity or metabolic mechanisms; evidence class: preclinical (population or model: Human participants or patients mentioned; study design: Human clinical study; outcome measure: endocannabinoid enzyme activity or metabolic mechanisms). PMID 34179865

    Evidence class: preclinical; Study design: Human clinical study. Source: Targeting the endocannabinoid system for management of HIV-associated neuropathic pain: A systematic review.
  2. Evidence row 300

    Endocannabinoids modulates endocannabinoid enzyme activity or metabolic mechanisms; evidence class: insufficient (study design: Narrative or expert review; outcome measure: endocannabinoid enzyme activity or metabolic mechanisms). PMID 32203086

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Potential application of endocannabinoid system agents in neuropsychiatric and neurodegenerative diseases-focusing on FAAH/MAGL inhibitors.
  3. Evidence row 301

    Endocannabinoids modulates endocannabinoid enzyme activity or metabolic mechanisms; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: endocannabinoid enzyme activity or metabolic mechanisms). PMID 40269679

    Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Inhibition of endocannabinoid hydrolases MAGL, FAAH and ABHD6 by AKU-005 reduces ex vivo cortical spreading depression.
  4. Evidence row 302

    Endocannabinoids modulates endocannabinoid enzyme activity or metabolic mechanisms; evidence class: insufficient (study design: Narrative or expert review; outcome measure: endocannabinoid enzyme activity or metabolic mechanisms). PMID 34217798

    Evidence class: insufficient; Study design: Narrative or expert review. Source: The role of endocannabinoid pathway in the neuropathology of Alzheimer's disease: Can the inhibitors of MAGL and FAAH prove to be potential therapeutic targets against the cognitive impairment associated with Alzheimer's disease?
  5. Evidence row 303

    THC modulates endocannabinoid enzyme activity or metabolic mechanisms; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: endocannabinoid enzyme activity or metabolic mechanisms). PMID 20047159

    Evidence class: insufficient; Study design: Narrative or expert review. Source: FAAH and MAGL inhibitors: therapeutic opportunities from regulating endocannabinoid levels.
  6. Evidence row 304

    Endocannabinoids modulates endocannabinoid enzyme activity or metabolic mechanisms; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: endocannabinoid enzyme activity or metabolic mechanisms). PMID 34959715

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Potential of Fatty Acid Amide Hydrolase (FAAH), Monoacylglycerol Lipase (MAGL), and Diacylglycerol Lipase (DAGL) Enzymes as Targets for Obesity Treatment: A Narrative Review.
  7. Evidence row 305

    Endocannabinoids modulates endocannabinoid enzyme activity or metabolic mechanisms; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: endocannabinoid enzyme activity or metabolic mechanisms). PMID 41092478

    Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Inhibition of endocannabinoid synthesis enzymes DAGL and NAPE-PLD transiently lowers body weight and alters glucose homeostasis during a high-fat diet challenge in mice.
  8. Evidence row 306

    Endocannabinoids modulates endocannabinoid enzyme activity or metabolic mechanisms; evidence class: preclinical (population or model: Animal model mentioned; study design: Animal study; outcome measure: endocannabinoid enzyme activity or metabolic mechanisms). PMID 24346263

    Evidence class: preclinical; Study design: Animal study. Source: Subcellular localization of NAPE-PLD and DAGL-α in the ventromedial nucleus of the hypothalamus by a preembedding immunogold method.
  9. Evidence row 307

    Endocannabinoids modulates endocannabinoid enzyme activity or metabolic mechanisms; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: endocannabinoid enzyme activity or metabolic mechanisms). PMID 39245706

    Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Microglial morphological/inflammatory phenotypes and endocannabinoid signaling in a preclinical model of periodontitis and depression.
  10. Evidence row 308

    Endocannabinoids modulates endocannabinoid enzyme activity or metabolic mechanisms; evidence class: insufficient (study design: Narrative or expert review; outcome measure: endocannabinoid enzyme activity or metabolic mechanisms). PMID 17346227

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Critical enzymes involved in endocannabinoid metabolism.
  11. Evidence row 309

    THC modulates endocannabinoid enzyme activity or metabolic mechanisms; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: endocannabinoid enzyme activity or metabolic mechanisms). PMID 39747798

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Chemical Probes for Investigating the Endocannabinoid System.
  12. Evidence row 310

    Endocannabinoids modulates endocannabinoid enzyme activity or metabolic mechanisms; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: endocannabinoid enzyme activity or metabolic mechanisms). PMID 30564946

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Structural properties and role of the endocannabinoid lipases ABHD6 and ABHD12 in lipid signalling and disease.
  13. Evidence row 311

    THC modulates endocannabinoid enzyme activity or metabolic mechanisms; evidence class: preliminary human (population or model: Pregnancy, lactation, or reproductive context mentioned; outcome measure: endocannabinoid enzyme activity or metabolic mechanisms). PMID 32829065

    Evidence class: preliminary human. Source: Impact of tetrahydrocannabinol on the endocannabinoid 2-arachidonoylglycerol metabolism: ABHD6 and ABHD12 as novel players in human placenta.
  14. Evidence row 312

    Endocannabinoids modulates endocannabinoid enzyme activity or metabolic mechanisms; evidence class: insufficient (study design: Narrative or expert review; outcome measure: endocannabinoid enzyme activity or metabolic mechanisms). PMID 21418147

    Evidence class: insufficient; Study design: Narrative or expert review. Source: The serine hydrolases MAGL, ABHD6 and ABHD12 as guardians of 2-arachidonoylglycerol signalling through cannabinoid receptors.
  15. Evidence row 313

    Endocannabinoids modulates endocannabinoid enzyme activity or metabolic mechanisms; evidence class: preclinical (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: endocannabinoid enzyme activity or metabolic mechanisms). PMID 30075103

    Evidence class: preclinical; Study design: Animal study. Source: Deregulation of the endocannabinoid system and therapeutic potential of ABHD6 blockade in the cuprizone model of demyelination.
  16. Evidence row 314

    Endocannabinoids modulates endocannabinoid enzyme activity or metabolic mechanisms; evidence class: preliminary human (population or model: Human participants or patients mentioned; outcome measure: endocannabinoid enzyme activity or metabolic mechanisms). PMID 22969151

    Evidence class: preliminary human. Source: Biochemical and pharmacological characterization of human α/β-hydrolase domain containing 6 (ABHD6) and 12 (ABHD12).
  17. Evidence row 1079

    2-AG studied for 2-AG biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: insufficient (study design: Narrative or expert review; outcome measure: 2-AG biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms). PMID 21418147

    Evidence class: insufficient; Study design: Narrative or expert review. Source: The serine hydrolases MAGL, ABHD6 and ABHD12 as guardians of 2-arachidonoylglycerol signalling through cannabinoid receptors.